Haemonetics Corp Earnings

Haemonetics Corp’s revenue fell -3.7% since last year same period to $330.6Mn in the Q1 2025. On a quarterly growth basis, Haemonetics Corp has generated -5.15% fall in its revenue since last 3-months.

Haemonetics Corp’s net profit jumped 184.68% since last year same period to $57.98Mn in the Q1 2025. On a quarterly growth basis, Haemonetics Corp has generated 54.64% jump in its net profits since last 3-months.

Haemonetics Corp’s net profit margin jumped 195.61% since last year same period to 17.54% in the Q1 2025. On a quarterly growth basis, Haemonetics Corp has generated 63.03% jump in its net profit margins since last 3-months.

Haemonetics Corp’s price-to-earnings ratio after this Q1 2025 earnings stands at 22.59.

Haemonetics Corp’s earning per share (EPS) estimates for the current quarter stand at 1.02 - a -16.39% fall from last quarter’s estimates.

Haemonetics Corp’s earning per share (EPS) estimates for the current year stand at 1.02.

Haemonetics Corp’s earning per share (EPS) jumped 37.78% since last year same period to 1.24 in the Q1 2025. This indicates that the Haemonetics Corp has generated 37.78% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Haemonetics Corp’s return on assets (ROA) stands at 0.07.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Haemonetics Corp’s return on equity (ROE) stands at 0.19.